DEAPR: Differential Expression and Pathway Ranking Tool Demonstrates NRAS and NRAS Mutations Have Differing Effects...

Area of Science:

• Oncology
• Genetics
• Bioinformatics

Background:

• NRAS mutations occur in 10% of acute myeloid leukemia (AML) patients, often at codon 12.
• Little is known about how specific NRAS G12 mutations impact cancer cell activity.

Purpose of the Study:

• To investigate the distinct effects of NRAS mutations on gene expression and cellular pathways in AML.
• To compare gene expression profiles between AML THP-1 cells with NRAS mutations and modified THP-1 cells.

Main Methods:

• Utilized a novel bioinformatic technique, differential expression and pathway ranking (DEAPR).
• Compared gene expression in AML THP-1 cells with NRAS mutations against B11 cells (NRAS-null THP-1 derived with inducible NRAS).

Main Results:

• Identified 1456 differentially expressed (DE) genes unique to the NRAS mutation and 585 DE genes specific to the NRAS mutation.
• The innate immune system pathway was prominent in both mutant-specific gene lists.
• Calprotectin genes (S100A8, S100A9) showed differential regulation related to NRAS mutation status.

Conclusions:

• The DEAPR strategy revealed significant differences between NRAS mutations.
• Findings suggest that distinct NRAS mutations may necessitate different therapeutic approaches in AML.